Tirzepatide Peptide Dosage: How the Schedule Works in Practice

Step 1, Starting at 2.5 mg: settling your system before anything else

The tirzepatide peptide dosage sequence opens at 2.5 mg for a specific reason: nausea and other gastrointestinal effects are most likely in the first few weeks, and the starter dose keeps those effects manageable while your gut adapts to the medicine. At this strength, most people notice modest appetite changes but little dramatic weight movement. That is expected. The job of this first pen is adjustment, not results.

You stay at 2.5 mg for at least four weeks. When your prescription is reviewed (every repeat at nume goes back to a real prescriber before anything is dispensed) the clinical team will consider whether you tolerated the starting dose well enough to move up. If side effects are still significant, staying put for another cycle is a legitimate clinical decision.

Practically speaking, the pen itself is a pre-filled KwikPen containing four weekly doses. It arrives via DPD in plain, unbranded packaging with a tracking link, straightforward to spot in your delivery notifications. Storage is in the fridge at 2–8 °C; the patient information leaflet gives the exact window for room-temperature use if needed.

The NHS medicines page for tirzepatide explains the general side-effect profile and what to watch for as you begin.

Step 2 (Moving through 5 mg, 7.5 mg and 10 mg: where therapeutic effect builds

Once the 2.5 mg period is complete, the next move is to 5 mg, then 7.5 mg, then 10 mg) each held for roughly four weeks. This is where most people begin to notice meaningful appetite suppression, and where the dual GIP and GLP-1 receptor mechanism has room to do more. Hunger between meals eases; portions feel like enough sooner.

The titration is not a rigid ladder. A prescriber can hold any dose for longer if GI symptoms are still present, or if there are other clinical reasons to take the increase more slowly. What matters is that every step is clinically reviewed, not auto-advanced by a system. For a closer look at what 5 mg feels like in practice, the Mounjaro 5 mg page covers that dose specifically.

Side effects at these mid-range doses follow the same pattern as at 2.5 mg but may intensify briefly after each increase: nausea, loose stools, constipation, reflux and burping are the most commonly reported. They typically settle within one to two weeks. Staying hydrated and eating smaller, lower-fat meals helps. Anyone experiencing severe or persistent stomach pain (particularly pain that radiates to the back) should seek urgent medical attention; the MHRA highlighted this as a serious but infrequent risk across GLP-1 medicines in a 2026 Drug Safety Update.

If you want to understand how tirzepatide dosing decisions are made in more detail, including what prompts a prescriber to hold rather than advance, that page goes deeper on the clinical reasoning.

Step 3 (Reaching 12.5 mg and 15 mg: the maintenance range

The upper end of the tirzepatide peptide dosage chart) 12.5 mg and 15 mg, is where the largest average weight reductions in clinical trials were recorded. In SURMOUNT-1, published in the New England Journal of Medicine, participants on 15 mg achieved an average body-weight reduction of around 20–21% over 72 weeks. NICE's appraisal of tirzepatide (TA1026) draws on this and other evidence when setting its recommendation thresholds.

Not everyone reaches 15 mg, and that is not a failure. The licensed maximum is the ceiling, not the target for every patient. Your prescriber determines the highest dose you tolerate well and that is driving clinically meaningful progress. For some people, 10 mg is the right long-term maintenance dose. For those interested in how 10 mg fits into the wider picture, the 10 mg dosage page covers that specifically.

At the maintenance dose, the focus shifts from titration to review: is the treatment continuing to work, are there any new side effects, and is the lifestyle programme alongside it still in place? NICE guidance notes that if weight loss is less than 5% after six months at the highest tolerated dose, continuing treatment should be reviewed. That review is a clinical conversation, not an automatic stop.

Anyone curious about what private treatment costs across the dose range will find context on the Mounjaro pricing page, which sets out how the UK market is structured without tying headline prices to a dose automatically.

Who the UK dosage schedule applies to, and who it does not

The tirzepatide dosage schedule described here covers the weight-management licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Tirzepatide is not licensed for use in people under 18, during pregnancy, while breastfeeding, or in those who are trying to conceive. Anyone with a history of medullary thyroid carcinoma or MEN2 syndrome should discuss this with a prescriber before considering it.

The dosage schedule is the same regardless of whether treatment is accessed privately or, for those who meet the criteria, through the NHS weight management pathway. The clinical logic (start low, increase slowly, hold at the dose that works) does not change by route. What differs is how quickly assessment and prescribing can happen.

Our Mounjaro treatment page sets out the full picture of what tirzepatide is, how it works and what the UK clinical programme looks like for those starting from the beginning. For a broader look at your options, our treatment overview is a good place to start before speaking to a prescriber.